Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Eisai Co., Ltd. (4523.T)
Tokyo, JP
Eisai Co., Ltd. is a Japanese pharmaceutical firm that develops, manufactures, and markets a broad spectrum of medical and healthcare products. Its significant therapeutic contributions include Aricept, prescribed for individuals with Alzheimer's disease and dementia with Lewy bodies; Methycobal, targeting peripheral neuropathy; and Fycompa, an antiepileptic medication used as an adjunctive treatment for partial-onset and primary generalized tonic-clonic seizures. The company's product line further encompasses Lyrica for pain management, and Dayvigo, an anti-insomnia agent formulated for adults. In the field of oncology, Eisai offers Lenvima, a molecularly targeted anticancer drug utilized for thyroid cancer, renal cell carcinoma (when administered alongside everolimus), and hepatocellular carcinoma. Another key cancer treatment is Halaven, an anticancer agent functioning as a microtubule dynamics inhibitor, indicated for breast cancer and liposarcoma. Additionally, Eisai provides Pariet, a proton-pump inhibitor effective in managing gastric and duodenal ulcers, reflux esophagitis, and the eradication of Helicobacter pylori infections. It also distributes Humira, a fully human anti-TNF-alpha monoclonal antibody employed in the treatment of autoimmune disorders such as rheumatoid arthritis. For consumer wellness, its offerings include Chocola BB plus, a vitamin B2 supplement beneficial for rough skin and stomatitis, along with a diverse collection of other items, such as third-class over-the-counter (OTC) drugs, designated quasi-drugs, and health-promoting foods. Originally established in 1941 under the name Nihon Eisai Co., Ltd., the company adopted its current name, Eisai Co., Ltd., in 1955 and operates from its headquarters in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.48% | -3.10% | -8.73% | -10.72% | -4.51% | -6.75% | +17.60% | -46.76% | -35.14% | -32.40% | +137.45% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 8 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+4.6% Q1'26: +9.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-16.5% Q1'26: -443.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+3.3% ★ Q1'26: -0.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+4.9% Q1'26: -4.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.7% Q1'26: -2.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.6% ★ Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.33× ★ Q1'26: -553.81× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 13 Rev. Ana. 13 EPS Ana. |
Mar 2027 8 Rev. Ana. 9 EPS Ana. |
Mar 2028 12 Rev. Ana. 12 EPS Ana. |
Mar 2029 6 Rev. Ana. 6 EPS Ana. |
Mar 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
548.47B
est: 550.66B (-0.4%)
|
547.92B
est: 556.04B (-1.5%)
|
539.10B
est: 545.37B (-1.2%)
|
600.05B
est: 601.17B (-0.2%)
|
642.83B
est: 639.87B (+0.5%)
|
695.62B
est: 682.84B (+1.9%)
|
645.94B
est: 664.47B (-2.8%)
|
756.23B
est: 739.40B (+2.3%)
|
744.40B
est: 754.23B (-1.3%)
|
741.75B
est: 733.85B (+1.1%)
|
789.40B
est: 775.39B (+1.8%)
|
821.36B
793.58B – 838.74B
+5.9% YoY
|
880.73B
869.78B – 891.42B
+7.2% YoY
|
933.22B
875.62B – 997.61B
+6.0% YoY
|
941.03B
939.05B – 943.01B
+0.8% YoY
|
1.02T
980.01B – 1.06T
+8.2% YoY
|
| EBITDA |
66.72B
est: 71.92B (-7.2%)
|
76.84B
est: 72.62B (+5.8%)
|
77.69B
est: 71.23B (+9.1%)
|
101.78B
est: 78.52B (+29.6%)
|
126.76B
est: 83.57B (+51.7%)
|
172.38B
est: 89.18B (+93.3%)
|
92.84B
est: 86.78B (+7.0%)
|
98.02B
est: 96.57B (+1.5%)
|
79.20B
est: 98.51B (-19.6%)
|
86.15B
est: 85.15B (+1.2%)
|
103.73B
est: 89.97B (+15.3%)
|
95.31B
92.09B – 97.33B
+5.9% YoY
|
102.20B
100.93B – 103.44B
+7.2% YoY
|
108.29B
101.61B – 115.76B
+6.0% YoY
|
109.20B
108.97B – 109.42B
+0.8% YoY
|
118.18B
113.72B – 123.06B
+8.2% YoY
|
| EBIT |
27.78B
est: 42.81B (-35.1%)
|
42.78B
est: 43.22B (-1.0%)
|
51.21B
est: 42.39B (+20.8%)
|
75.60B
est: 46.73B (+61.8%)
|
99.92B
est: 49.74B (+100.9%)
|
138.68B
est: 53.08B (+161.3%)
|
56.54B
est: 51.65B (+9.5%)
|
59.62B
est: 57.48B (+3.7%)
|
39.22B
est: 58.63B (-33.1%)
|
46.75B
est: 47.57B (-1.7%)
|
63.82B
est: 50.26B (+27.0%)
|
53.24B
51.44B – 54.37B
+5.9% YoY
|
57.09B
56.38B – 57.79B
+7.2% YoY
|
60.50B
56.76B – 64.67B
+6.0% YoY
|
61.00B
60.87B – 61.13B
+0.8% YoY
|
66.02B
63.53B – 68.75B
+8.2% YoY
|
| Net Income |
43.25B
est: 31.25B (+38.4%)
|
54.93B
est: 42.83B (+28.3%)
|
39.36B
est: 40.02B (-1.6%)
|
51.85B
est: 55.03B (-5.8%)
|
63.39B
est: 61.76B (+2.6%)
|
121.77B
est: 101.60B (+19.9%)
|
42.12B
est: 46.61B (-9.6%)
|
47.95B
est: 57.67B (-16.8%)
|
55.43B
est: 57.00B (-2.7%)
|
42.41B
est: 32.65B (+29.9%)
|
46.43B
est: 45.48B (+2.1%)
|
45.54B
38.97B – 48.27B
+0.1% YoY
|
61.41B
57.68B – 62.72B
+34.8% YoY
|
69.03B
52.67B – 108.58B
+12.4% YoY
|
74.47B
55.63B – 110.15B
+7.9% YoY
|
104.18B
99.07B – 109.78B
+39.9% YoY
|
| SGA |
189.91B
est: 263.83B (-28.0%)
|
185.87B
est: 266.40B (-30.2%)
|
175.61B
est: 261.29B (-32.8%)
|
179.92B
est: 288.03B (-37.5%)
|
218.89B
est: 306.57B (-28.6%)
|
246.18B
est: 327.16B (-24.8%)
|
269.82B
est: 318.35B (-15.2%)
|
352.14B
est: 354.25B (-0.6%)
|
347.56B
est: 361.36B (-3.8%)
|
363.93B
est: 359.51B (+1.2%)
|
393.86B
est: 379.86B (+3.7%)
|
402.39B
388.77B – 410.90B
+5.9% YoY
|
431.47B
426.10B – 436.71B
+7.2% YoY
|
457.18B
428.97B – 488.73B
+6.0% YoY
|
461.01B
460.04B – 461.98B
+0.8% YoY
|
498.92B
480.11B – 519.53B
+8.2% YoY
|
| EPS |
151.57
est: 110.21 (+37.5%)
|
192.23
est: 151.06 (+27.3%)
|
137.62
est: 141.14 (-2.5%)
|
181.18
est: 194.09 (-6.7%)
|
221.34
est: 217.83 (+1.6%)
|
425.01
est: 358.33 (+18.6%)
|
146.95
est: 164.37 (-10.6%)
|
167.27
est: 203.39 (-17.8%)
|
193.31
est: 201.11 (-3.9%)
|
147.86
est: 113.88 (+29.8%)
|
163.76
est: 160.96 (+1.7%)
|
155.21
138.24 – 171.23
-3.6% YoY
|
213.56
204.62 – 222.50
+37.6% YoY
|
247.70
186.86 – 385.18
+16.0% YoY
|
271.34
197.34 – 390.75
+9.5% YoY
|
369.58
351.46 – 389.43
+36.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.87% | 9.89M | 0.40% |
| 2 | UBS S&P Dividend Aristocrats ESG Elite UCITS ETF USD dis UBUM.DE | 0.69% | 1.43M | 0.30% |
| 3 | iShares Ageing Population UCITS ETF AGED.L | 0.54% | 4.77M | 0.40% |
| 4 | iShares MSCI Global Sustainable Development Goals ETF SDG | 0.46% | 771.5K | 0.50% |
| 5 | Sparkline International Intangible Value ETF DTAN | 0.43% | 63.0K | 0.55% |
| 6 | Amundi MSCI Japan ESG Broad Transition UCITS ETF EUR Acc J1GR.DE | 0.39% | 5.78M | 0.15% |
| 7 | iShares MSCI World Health Care Sector Advanced UCITS ETF WHCA.AS | 0.35% | 1.17M | 0.18% |
| 8 | iShares MSCI World Health Care Sector Advanced UCITS ETF WHCS.AS | 0.35% | 2.16M | 0.18% |
| 9 | Goldman Sachs ActiveBeta Japan Equity ETF GSJY | 0.33% | 278.4K | 0.25% |
| 10 | iShares MSCI Japan Value ETF EWJV | 0.28% | 1.93M | 0.15% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lynn D. Kramer FAAN | Vice President & Chief Clinical Officer | 305M | — |
| Gary Hendler | Senior Vice President & President of EMEA Region | 198M | male |
| Yanhui Feng | Senior Vice President | 191M | female |
| Haruo Naito | Chief Executive Officer, Representative Corporate Officer & Director | 190M | male |
| Keisuke Naito | Representative Corporate Officer, EVP, COO & Chief Growth Officer | — | male |
| Makoto Hoketsu | Vice President & Chief Information Officer | — | — |
| Shin Kato | Vice President, General Counsel & Chief Compliance Officer | — | — |
| Takuya Oyama | Vice President, Chief Financial Officer & Chief IR Officer | — | male |
| Teruyuki Masaka | Vice President and Chief HR Officer, Corporate Communications, Sustainability & General Affairs | — | male |
| Katsutoshi Ido | Vice President, Chief Scientific Officer & Head of DHBL Discoverry | — | — |
| Akiko Nakahama | Vice President of Japan Regulatory Affairs, Manufacturing, Quality & Technology | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4523.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
